Nebivolol Zentiva (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Zentiva, is a beta blocker presented as a tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure and improving cardiovascular outcomes.

GNH USA supplies Nebivolol Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic receptor blocker used in the management of cardiovascular conditions.

- Essential hypertension: provides sustained reduction of high blood pressure. - Secondary hypertension: assists in controlling blood pressure when caused by another condition. - Isolated systolic hypertension: lowers systolic pressure to reduce cardiovascular risk.

Nebivolol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain in the head. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: general feeling of tiredness. - Nausea: upset stomach or urge to vomit. - Bradycardia: slower than normal heart rate. - Peripheral edema: mild swelling of the ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Atrioventricular block: impaired electrical conduction in the heart. - Bronchospasm: tightening of airway muscles, especially in asthmatic patients. - Hypotension: dangerously low blood pressure. - Hepatic dysfunction: abnormal liver enzyme elevations. - Anaphylactic reaction: rare severe allergic response.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Blood pressure monitoring: ensure adequate control and avoid excessive lowering. - Heart rate assessment: watch for bradycardia, especially in patients with conduction disorders. - Asthma/COPD caution: use carefully in patients with reactive airway disease. - Discontinuation: avoid abrupt withdrawal to prevent rebound hypertension. - Renal impairment: adjust therapy based on renal function. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Non‑selective beta blockers: may cause additive bradycardia. - Calcium channel blockers (verapamil, diltiazem): increase nebivolol plasma levels. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): reduce metabolism, raising drug exposure.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect, risking hypotension. - ACE inhibitors or ARBs: combined use may lead to excessive blood pressure reduction. - Antidiabetic agents: nebivolol may mask hypoglycemia symptoms.